BBK Worldwide Unveils "Adaptive Recruitment" Reshaping Patient Recruitment For Clinical Trials - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
BBK Worldwide Unveils "Adaptive Recruitment" Reshaping Patient Recruitment For Clinical Trials New R&D Model Protects Performance in a Threatened Enrollment Landscape


BBK Worldwide Unveils "Adaptive Recruitment" Reshaping Patient Recruitment For Clinical Trials

New R&D Model Protects Performance in a Threatened Enrollment Landscape

PR Newswire

SAN DIEGO and BOSTON, June 16, 2014 /PRNewswire/ -- DIA 2014 50th Annual Meeting -- BBK Worldwide, the leader in patient recruitment, today unveiled a new specialty in clinical trial marketing: adaptive  recruitment. Designed specifically to protect global enrollment integrity, within a changing or threatened landscape, adaptive recruitment helps sites and sponsors maximize tight budgets and timeframes by offering the tools and best-practices needed to ensure more informed recruitment and enrollment decisions – and the ability to seamlessly employ real-time corrections as needed. BBK Principal Matthew Stumm will discuss this new model in detail during his DIA Annual Meeting presentation, "Adopting New Strategies for the New Face of Patient Recruitment," on Tuesday, June 17 at 2:45 p.m. PST.

BBK Worldwide

Technological advances and market consolidation continue to reshape the clinical research landscape at a record pace, while issues relating to patient recruitment and enrollment continue to be cited as a top cause of study initiation delays. Leveraging its 30-year history and patient recruitment expertise, BBK's adaptive recruitment model relies on BBK's robust TrialCentralNet (SM) (TCN®) recruitment platform and comprises three core elements: approachable and flexible technology, strategic branding and advertising, and sophisticated enrollment data analysis. Embracing this adaptive discipline fosters an empowered and collaborative study community capable of making informed decisions based on data versus anecdotal information. Further, this data-centric approach allows teams to make decisions at critical study milestones and respond more rapidly to previously unforeseen enrollment challenges.

"We pioneered this market to help address the challenges specific to patient recruitment and retention, and remain committed to ensuring that our pharmaceutical, biopharmaceutical and medical device clients have the support they need to maximize budgets and enroll global studies on time," said Joan F. Bachenheimer, Founding Principal, BBK Worldwide. "We know, from having successfully managed thousands of studies worldwide, that success is predicated on a mix of technologies, expert data analysis and strategic branding and advertising."

"This new adaptive recruitment approach embraces today's technological innovations and communication channels – from data analytics and mobile to social and streaming radio – to remove the guesswork about what works and what doesn't. Sponsors and sites can monitor patient data in real-time and pivot as needed based on the data, not some preconceived notion about how tactics work in a certain region with a particular demographic," continued Bachenheimer. "As technology continues to reshape the ways in which we reach patients and manage studies, so too must our methodologies and processes. At last the industry is beginning to embrace these shifts and leverage the data as it was intended to be leveraged. It's an exciting time."

About BBK Worldwide

With more than three decades of experience across a wide variety of therapies and medicines, BBK Worldwide is the global leader in patient recruitment for the clinical trial industry. BBK's latest innovation is the introduction of adaptive recruitment – a new specialty in clinical trial marketing proven to protect global enrollment integrity, specifically within a changing or threatened landscape. BBK is a privately held, women owned business, headquartered in Needham, Mass. For more information, visit: www.bbkworldwide.com.

Logo - http://photos.prnewswire.com/prnh/20140604/94427

SOURCE BBK Worldwide

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
7%
Create entirely its own pathway program?
7%
View Results
Untitled Document

Click here